Structure-activity relationship analysis of 3-phenylpyrazole derivatives as androgen receptor antagonists

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Oncology

Background:

• Prostate cancer (PCa) is a leading cause of cancer incidence in men.
• Androgen receptor (AR) antagonists are primary PCa therapeutics, but drug resistance is a major challenge.
• Existing 3-phenylpyrazole derivatives show potential AR antagonism but require efficiency improvements.

Purpose of the Study:

• To investigate structure-activity relationships (SAR) of 3-phenylpyrazole derivatives as AR antagonists.
• To identify key structural features for enhancing the efficacy of novel AR antagonists.
• To provide insights for the rational design of next-generation PCa therapeutics.

Main Methods:

• Employed comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA).
• Utilized two distinct strategies for optimal molecular conformation alignment: atomic alignment and molecular docking.
• Developed predictive models to correlate chemical structure with androgenic bioactivity.

Main Results:

• Both atomic alignment and molecular docking strategies yielded satisfactory predictive models.
• Atomic alignment demonstrated slightly superior performance compared to molecular docking.
• The developed models successfully highlighted critical structural determinants for AR antagonism.

Conclusions:

• The study provides valuable SAR insights for 3-phenylpyrazole derivatives targeting AR.
• Atomic alignment is a robust method for conformational analysis in drug design.
• Findings offer a foundation for designing more potent and effective AR antagonists for prostate cancer treatment.